<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262856</url>
  </required_header>
  <id_info>
    <org_study_id>AB154CSP0002</org_study_id>
    <nct_id>NCT04262856</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer</brief_title>
  <acronym>ARC-7</acronym>
  <official_title>A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase 2 open-label study will evaluate the safety and efficacy of&#xD;
      zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and&#xD;
      domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1&#xD;
      positive, metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label phase 2 study in participants with non-small cell lung cancer which&#xD;
      will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in&#xD;
      combination with other immunotherapeutics across multiple treatment arms.&#xD;
&#xD;
      Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab,&#xD;
      2) zimberelimab + domvanalimab (anti-TIGIT antibody), 3) zimberelimab + domvanalimab +&#xD;
      etrumadenant (dual adenosine receptor antagonist). Participants that progress on the&#xD;
      zimberelimab monotherapy arm may cross-over to receive the third arm combination of&#xD;
      zimberelimab + domvanalimab + etrumadenant.&#xD;
&#xD;
      The primary objective of this clinical study is to evaluate the efficacy of each combination&#xD;
      therapy by assessing: 1) objective response rate (ORR) of participants with measurable&#xD;
      disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free&#xD;
      survival (PFS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">June 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From randomization until death from any cause (up to approximately 3-5 years)</time_frame>
    <description>ORR as assessed by RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From randomization until death from any cause (up to approximately 3-5 years)</time_frame>
    <description>PFS as assessed by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From the date of first occurence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
    <description>DoR as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From the date of first occurence of a documented objective response to first documentation of disease progression on death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
    <description>DCR as assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From Screening until up to 100 days after the last dose (approximately 2 years)</time_frame>
    <description>The number and percentage of participants that experience an adverse event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of zimberelimab</measure>
    <time_frame>Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years).</time_frame>
    <description>Plasma concentration of zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of domvanalimab</measure>
    <time_frame>Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years).</time_frame>
    <description>Plasma concentration of domvanalimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of etrumadenant</measure>
    <time_frame>Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years).</time_frame>
    <description>Plasma concentration of etrumadenant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of zimberelimab</measure>
    <time_frame>Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).</time_frame>
    <description>Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of domvanalimab</measure>
    <time_frame>Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).</time_frame>
    <description>Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Nonsquamous Non Small Cell Lung Cancer</condition>
  <condition>Squamous Non Small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (zimberelimab monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zimberelimab monotherapy by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (domvanalimab and zimberelimab combination therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive domvanalimab in combination with zimberelimab by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral etrumadenant in combination with zimberelimab and domvanalimab by IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Zimberelimab is a fully human anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Arm 1 (zimberelimab monotherapy)</arm_group_label>
    <arm_group_label>Arm 2 (domvanalimab and zimberelimab combination therapy)</arm_group_label>
    <arm_group_label>Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domvanalimab</intervention_name>
    <description>Domvanalimab is a humanized monoclonal antibody targeting human TIGIT</description>
    <arm_group_label>Arm 2 (domvanalimab and zimberelimab combination therapy)</arm_group_label>
    <arm_group_label>Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)</arm_group_label>
    <other_name>AB154</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrumadenant</intervention_name>
    <description>Etrumadenant is an A2aR and A2bR antagonist</description>
    <arm_group_label>Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)</arm_group_label>
    <other_name>AB928</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants; age â‰¥ 18 years&#xD;
&#xD;
          -  Histologically confirmed squamous or nonsquamous, PD-L1 positive, NSCLC that is&#xD;
             metastatic without sensitizing epidermal growth factor receptor (EGFR) or anaplastic&#xD;
             lymphoma kinase (ALK) mutation expression&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1&#xD;
&#xD;
          -  Must have at least 1 measurable lesion per RECIST v1.1&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases within 28 days of first dose&#xD;
&#xD;
          -  Concurrent medical condition requiring the use of supra-physiologic doses of&#xD;
             corticosteroids (&gt; 10 mg/day of oral prednisone or equivalent) or immunosuppressive&#xD;
             medications&#xD;
&#xD;
          -  Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody or&#xD;
             Hepatitis C qualitative RNA or human immunodeficiency virus-1 (HIV-1) antibody&#xD;
&#xD;
          -  Any active autoimmune disease or a documented history of autoimmune disease or&#xD;
             syndrome that required systemic treatment in the past 2 years (ie, with use of&#xD;
             disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for&#xD;
             vitiligo or resolved childhood asthma/atopy.&#xD;
&#xD;
          -  Prior malignancy active within the previous 2 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6220</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naik Gurudatta</last_name>
      <email>alkanand@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Aparna Hegde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Maniam</last_name>
      <email>ajitm@pacificcancer.com</email>
    </contact>
    <investigator>
      <last_name>Ajit Maniam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Center</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Irvine Neuropsychiatric Center-University of California</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Redlands Community Hospital</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Ramos</last_name>
      <phone>909-478-7973</phone>
      <email>PRamos@redlandshospital.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Emad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Foster</last_name>
      <phone>707-521-3836</phone>
    </contact>
    <investigator>
      <last_name>Ian Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute (ICRI)</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Michael Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Englewood</city>
        <state>Florida</state>
        <zip>34223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna-May Bernard</last_name>
      <phone>239-274-9930</phone>
      <phone_ext>0621</phone_ext>
      <email>donna.bernard@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Register</last_name>
      <phone>941-301-2293</phone>
      <email>mregister@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Simonetta</last_name>
      <email>msimonetta@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>VIjay Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Wright</last_name>
      <email>pwright@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Marksberry</last_name>
      <phone>772-567-2332</phone>
      <phone_ext>24526</phone_ext>
      <email>dianne.marksberry@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Sceniak</last_name>
      <phone>815-730-3098</phone>
      <email>ksceniak@jolietoncology.com</email>
    </contact>
    <investigator>
      <last_name>Nafisa Burhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Buntain</last_name>
      <email>Jennifer.Buntain@BHSI.com</email>
    </contact>
    <investigator>
      <last_name>Firas Badin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylee Fleig</last_name>
      <phone>502-629-3681</phone>
      <email>kylee.fleig@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Adam Lye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital East</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phyllis Thornton</last_name>
      <phone>502-721-6030</phone>
      <email>phyllis.thornton@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Wangjian Zhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery</last_name>
      <phone>504-842-0275</phone>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Hartman-Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigation Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elhamy Eskander</last_name>
      <email>eskander@fmh.org</email>
    </contact>
    <investigator>
      <last_name>Elhamy Eskander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center, PC</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasa Krstevski</last_name>
      <phone>248-747-4383</phone>
      <email>natasa.krstevski@michmer.com</email>
    </contact>
    <investigator>
      <last_name>Craig Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-288-2495</phone>
      <email>tmcbeth@forrestgeneral.com</email>
    </contact>
    <investigator>
      <last_name>John Hrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Healthcare</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Schroeder</last_name>
      <phone>816-276-3630</phone>
      <email>Molly.schroeder2@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Stillwill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigation Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89196</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Krishner</last_name>
      <phone>201-634-5792</phone>
      <email>kirsel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eli Krishner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-488-2918</phone>
      <phone_ext>121</phone_ext>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health Cancer Institute</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Garambone</last_name>
      <email>ngarambone@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Garofano</last_name>
      <phone>212-304-5686</phone>
      <email>rfg2115@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Henick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Kettler</last_name>
      <email>jkettler@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Jimmy Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center - Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Gadus</last_name>
      <phone>419-479-5605</phone>
      <phone_ext>5656</phone_ext>
      <email>tgadus@toledoclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rex Mowat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital (AGH)-Alleghney Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Gazarik</last_name>
      <phone>412-389-4650</phone>
      <email>Kathryn.Gazarik@AHN.ORG</email>
    </contact>
    <investigator>
      <last_name>Islam Mohammed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group, PC</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hadlock</last_name>
      <phone>570-887-2141</phone>
      <email>susan.hadlock@guthrie.org</email>
    </contact>
    <investigator>
      <last_name>Philip Lowry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health-Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bria Wilson</last_name>
      <phone>615-329-7642</phone>
      <email>bria.wilson@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center For Cancer And Blood Disorders (Texas Cancer Care)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayley Zimmerman</last_name>
      <email>hayley_zimmerman@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Ray Page, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr.John R Waldron, MD Off of</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anirudha Dasgupta</last_name>
      <phone>281-440-5006</phone>
      <email>adasgupta@wmrad.com</email>
    </contact>
    <investigator>
      <last_name>Anirudha Dasgupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Salas</last_name>
      <email>ssalas@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Yalamanchili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology-Oncology, P.A.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trikena Hampton</last_name>
      <phone>903-592-6152</phone>
      <phone_ext>137</phone_ext>
      <email>Trikena.Hampton@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <phone>540-728-0753</phone>
      <email>natasha.holt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Kusi</last_name>
      <phone>703-208-9286</phone>
      <email>charles.kusi@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates dba Summit Cancer Centers</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>509-462-2273</phone>
      <email>chaudhrym@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Arvind Chaudhry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Davis</last_name>
      <phone>509-668-4868</phone>
      <phone_ext>66245</phone_ext>
      <email>diane.davis2@confluencehealth.org</email>
    </contact>
    <investigator>
      <last_name>Lindsay Overton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqui McBurnie</last_name>
      <phone>61260641508</phone>
      <email>jacqui.mcburnie@bordermedonc.com.au</email>
    </contact>
    <investigator>
      <last_name>Christopher Steer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Dever</last_name>
      <phone>61266565733</phone>
      <email>robyn.dever@ncahs.health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>William Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shoalhaven Cancer Care Centre</name>
      <address>
        <city>Nowra</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Leighton</last_name>
      <phone>61242534384</phone>
      <email>carly.leighton@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Daniel Paul Brungs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Clark</last_name>
      <phone>61755067478</phone>
      <email>sharon.clark1@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Pawan Bajaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Rowe, MD</last_name>
      <phone>61882504111</phone>
      <email>Julie.Rowe@calvarycare.org.au</email>
    </contact>
    <investigator>
      <last_name>Rohit Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brampton Civic Hospital (Bch), William Osler Health Centre</name>
      <address>
        <city>Brampton</city>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Faure</last_name>
      <email>Lisa.Faure@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Henry Conter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)</name>
      <address>
        <city>MontrÃ©al</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Owen</last_name>
    </contact>
    <investigator>
      <last_name>Scott Owen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Integre de Sante et de Services Sociaux des Laurentides Hopital regional de Saint-Jerome</name>
      <address>
        <city>Saint Jerome</city>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanick Sardin-Laframboise</last_name>
      <phone>450-431-1020</phone>
    </contact>
    <investigator>
      <last_name>Ghislain Cournoyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Centre</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Chau</last_name>
      <phone>85223868002</phone>
      <email>katherine.chau@hkuoc.hk</email>
    </contact>
    <investigator>
      <last_name>Jacky Yu-Chung Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanity and Health Research Center</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Chung</last_name>
      <phone>85221169283</phone>
      <email>rick.chung@hnhmgl.com</email>
    </contact>
    <investigator>
      <last_name>Chi Pan Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Zhang Chan</last_name>
      <phone>6129902393</phone>
      <email>ctz520@ha.org.hk</email>
    </contact>
    <investigator>
      <last_name>Ashley Chi Kin Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital (Hong Kong)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leann Au</last_name>
      <phone>85235062851</phone>
      <email>awy897@ha.org.hk</email>
    </contact>
    <investigator>
      <last_name>Kam Hung Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taewon Jang</last_name>
    </contact>
    <investigator>
      <last_name>Taewon Jang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam University Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunyoung Ko</last_name>
      <email>ggingang@naver.com</email>
    </contact>
    <investigator>
      <last_name>Young-Chul Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohee Choi</last_name>
    </contact>
    <investigator>
      <last_name>HeeKyung Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miyoung Oh</last_name>
      <phone>82632593277</phone>
      <email>0175960343@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Yongchul Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garim Park</last_name>
      <phone>82317877003</phone>
      <email>pgarim96@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Seok Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeonwoo Chae</last_name>
    </contact>
    <investigator>
      <last_name>Yoon Ji Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeonghye Lee</last_name>
    </contact>
    <investigator>
      <last_name>Yun-Gyoo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>2841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeonwoo Chae</last_name>
      <phone>8229206950</phone>
      <email>aromee96@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sang Won Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Sook Kang</last_name>
      <phone>82230107282</phone>
      <email>yskang1@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Sang We Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhyun Jung</last_name>
      <phone>82222586546</phone>
      <email>tngusgmldud@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Hyoung Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent Hospital of the Catholic University of Korea</name>
      <address>
        <city>Suwon-si</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jungsoon Kim</last_name>
      <phone>82312498485</phone>
      <email>sella79@naver.com</email>
    </contact>
    <investigator>
      <last_name>Byoung Yong Shim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Uijeongbu</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prinicipal Investigator</last_name>
    </contact>
    <investigator>
      <last_name>Yoon Ho Ko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raffles Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Chunzi Yang</last_name>
      <phone>6563112305</phone>
      <email>yang_christie@rafflesmedical.com</email>
    </contact>
    <investigator>
      <last_name>Terence Aik Huang Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncocare Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Chen</last_name>
      <email>veraqxchen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Swan Swan Leong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Curie Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>329563</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ru Yi Ong</last_name>
      <phone>6597760476</phone>
      <email>ong.r.y@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chee Keong Toh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Ya Lin</last_name>
      <phone>88677317123</phone>
      <phone_ext>3681</phone_ext>
      <email>chanyai0725@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chin-Chou Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin-Chou Wang</last_name>
    </contact>
    <investigator>
      <last_name>Chin-Chou Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>New Taipei</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Ching Wang</last_name>
      <phone>886222490088</phone>
      <phone_ext>8170</phone_ext>
      <email>jj098686@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kang-Yun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ling Lai</last_name>
      <phone>886422653506</phone>
      <email>annalin310@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Thomas Tsao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital</name>
      <address>
        <city>Tainan City</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian Lee</last_name>
      <phone>88666226999</phone>
      <phone_ext>73232</phone_ext>
      <email>shiu880304@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wen-Tsung Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Ling Chen</last_name>
      <email>karenchen911@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-Wei Kuo</last_name>
      <phone>886287923311</phone>
      <phone_ext>16402</phone_ext>
      <email>a369512@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ching-Liang Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo-Yu Hsiung</last_name>
      <email>joyuhsiung@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pei-Shan Tsai</last_name>
      <phone>8862235623905</phone>
      <email>113598@ntuh.gov.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Jin-Yuan Shih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Cheng Hung</last_name>
      <phone>886929010711</phone>
      <email>YuCheng.Hung@novotech-smo.com</email>
    </contact>
    <investigator>
      <last_name>Kai-Ling Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsiao-Ying Yang</last_name>
      <phone>88633281200</phone>
      <phone_ext>2285</phone_ext>
      <email>daleyang2014@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chien-Ying Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

